Lamivudine Amarox (Lamivudine)

Lamivudine is converted inside cells to its active triphosphate form, which blocks the reverse transcriptase enzyme of HIV and the DNA polymerase of hepatitis B virus. This inhibition stops the addition of nucleotides to viral DNA, leading to premature chain termination and reduced viral replication.

The specific dose of Lamivudine Amarox is determined by the prescribing clinician based on the patient’s condition, age, weight, renal function, and other individual factors. Patients should follow the dosage instructions provided by their healthcare professional.

Safety data for lamivudine in pregnancy and lactation are limited. Healthcare providers weigh potential benefits against possible risks before prescribing it to pregnant or nursing individuals. Women should discuss any concerns with their physician.

To request Lamivudine Amarox, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details, and any necessary import documentation.

Lamivudine belongs to the nucleoside reverse transcriptase inhibitor (NRTI) class, offering a favorable safety profile and once‑daily dosing in many regimens. Compared with some protease inhibitors, it has fewer metabolic side effects, but it is often combined with other agents to achieve optimal viral suppression.

Lamivudine Amarox should be stored at ambient temperature, below 25 °C, in its original packaging to protect it from moisture and light. Keep the product out of reach of children and do not use it after the expiration date.

Lamivudine Amarox is taken orally, usually with or without food, as directed by a healthcare professional. The tablet should be swallowed whole with a glass of water and not crushed or chewed unless specifically instructed.

Serious adverse events, though rare, include lactic acidosis, severe hepatotoxicity, pancreatitis, and life‑threatening skin reactions such as Stevens‑Johnson syndrome. Patients should seek immediate medical attention if they experience unexplained abdominal pain, rapid breathing, severe fatigue, or skin rash.

Lamivudine Amarox is contraindicated in individuals with known hypersensitivity to lamivudine or any of its excipients. Patients with severe renal impairment may require dose adjustment, and those with active liver disease should be closely monitored. Always consult a healthcare provider before starting therapy.